Development and Characterization of the Novel Orally Bioavailable EZH1/2 Dual Inhibitor DS-3201

Blood20.30
Volume: 130, Pages: 2073 - 2073
Published: Dec 7, 2017
Abstract
Polycomb repressive complex 2 (PRC2) methylates histone H3 lysine 27 (H3K27) and represses gene expression to regulate cell proliferation and differentiation. Enhancer of zeste homolog 2 (EZH2) or its close homolog EZH1 function as catalytic subunits of PRC2, so there are two PRC2 complexes containing either EZH2 or EZH1. Many reports suggest that inhibiting PRC2 activity through EZH2 knockdown gives rise to anti-cancer effect against...
Paper Details
Title
Development and Characterization of the Novel Orally Bioavailable EZH1/2 Dual Inhibitor DS-3201
Published Date
Dec 7, 2017
Journal
Volume
130
Pages
2073 - 2073
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.